The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy

Nature Medicine

Volumn 6, Issue 1, 2000, Pages 82-85

  Ramratnam, Bharat ^a   Mittler, John E ^b   Zhang, Linqi ^a   Boden, Daniel ^a   Hurley, Arlene ^a   Fang, Fang ^a   Macken, Catherine A ^b   Perelson, Alan S ^b   Markowitz, Martin ^a   Ho, David D ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b LOS ALAMOS NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEMORY CELL; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; RESERVOIR; VIRUS REPLICATION;

ADULT; CELLS, CULTURED; CROSS-SECTIONAL STUDIES; HIV INFECTIONS; HIV-1; HOMOSEXUALITY, MALE; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; NEEDLESTICK INJURIES; RNA, VIRAL; TIME FACTORS; VIRAL LOAD; VIRUS LATENCY; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0033984045     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/71577     Document Type: Article

References (25)

1. Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295-1 300 (1997).
2. Wong, J.K. et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291-1295 (1997).
3. Chun, T-W. et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 94, 13193-13197 (1997).
4. Chun, T-W. et al. In vivo fate of HIV-1 infected cells: quantitative analysis of the transition to stable latency. Nature Med. 1, 1284-1290 (1995).
5. Chun, T-W. et al Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387, 183-188 (1997).
6. Ho, D.D. Toward HIV eradication or remission: the tasks ahead. Science 280, 1866-1867 (1998).
7. Zhang, L. et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N. Engl. J. Med. 340, 1605-1613 (1999).
8. Michie, C.A., McLean, A., Alcock, B. & Beverley, P.C. Lifespan of human lymphocyte subsets defined by CD45 isoforms. Nature 360, 264-265 (1992).
9. Hellerstein, M et al. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nature Med. 5. 83-89 (1999).
10. Mohri, H., Bonhoeffer, S., Monard, S., Perelson, A.S., Ho, D.D. Rapid turnover of T lymphocytes in SIV-infected rhesus macaques. Science 279, 1223-1227 (1998).
11. Finzi, D. et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Med. 5, 512-517 (1999).
12. Macken, C.A. Design and analysis of serial limiting dilution assays with small sample sizes. J. Immunol. Meth. 222, 13-29 (1999).
13. Perelson, A.S., Neumann, A.D., Markowitz, M., Leonard, J.M., Ho, D.D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span and viral generation time. Science 271, 1582-1586 (1996).
14. Wei, X. et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117-122 (1995).
15. Ho, D.D. et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-126 (1995).
16. Perelson, A.S. et al. Decay characteristics of HIV-1 infected compartments during combination therapy. Nature 387, 188-191 (1997).
17. Furtado, M.R. et al. Persistence of HIV-1 transcription in peripheral blood mononuclear cells in patients receiving potent antiretroviral therapy. N. Engl. J. Med. 340, 1614-1622 (1999).
18. Natarajan, V. et al. HIV-1 replication in patients with undetectable plasma virus receiving HAART. Lancet 353, 119-120 (1999).
19. Lewin, S.R. et al. The use of real-time PCR and molecular beacons to detect virus replication in HIV-1 infected individuals on prolonged effective antiretroviral therapy. J. Virol. 73, 6099-6103 (1999).
20. Gunthard, H.F. et al Higher selection pressure from antiretroviral drugs in vivo results in increased evolutionary distance in HIV-1 pol. Virology 259, 154-165 (1999).
21. Altice, F.L. & Friedland, G.H. The era of adherence to HIV therapy. Ann. Intern. Med. 129, 503-505 (1998).
22. Lucas, G.M., Chaisson, R.E. & Moore, R.D. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann. Intern. Med. 131, 81-87 (1999).
23. Palella, F.J. et al. Declining morbidity and mortality among patients with advanced human immunodeficiency. N. Engl. J. Med. 338, 853-860 (1998).
24. Ortiz, G.M. et al. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of HAART. J. Clin. Invest. 104,-R13-R18 (1999).
25. + T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nature Med. 5, 651-655 (1999).